

Jordi Bruna

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/907078/publications.pdf>

Version: 2024-02-01

141
papers

6,971
citations

81743

39
h-index

66788

78
g-index

147
all docs

147
docs citations

147
times ranked

8686
citing authors

#	ARTICLE	IF	CITATIONS
1	Serum neurofilament light chain levels as biomarker of paclitaxel-induced cognitive impairment in patients with breast cancer: a prospective study. <i>Supportive Care in Cancer</i> , 2022, 30, 1807-1814.	1.0	9
2	Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). <i>Neuro-Oncology</i> , 2022, 24, 755-767.	0.6	25
3	Synthesis and Validation of a Bioinspired Catechol-Functionalized Pt(IV) Prodrug for Preclinical Intranasal Glioblastoma Treatment. <i>Cancers</i> , 2022, 14, 410.	1.7	9
4	Voxel-level analysis of normalized DSC-PWI time-intensity curves: a potential generalizable approach and its proof of concept in discriminating glioblastoma and metastasis. <i>European Radiology</i> , 2022, 32, 3705-3715.	2.3	14
5	Prospectively assessing serum neurofilament light chain levels as a biomarker of paclitaxel-induced peripheral neurotoxicity in breast cancer patients. <i>Journal of the Peripheral Nervous System</i> , 2022, 27, 166-174.	1.4	21
6	Intranasal Administration of Catechol-Based Pt(IV) Coordination Polymer Nanoparticles for Glioblastoma Therapy. <i>Nanomaterials</i> , 2022, 12, 1221.	1.9	4
7	Cisplatin-induced peripheral neuropathy is associated with neuronal senescence-like response. <i>Neuro-Oncology</i> , 2021, 23, 88-99.	0.6	36
8	Plasticity in bilateral hippocampi after a 3-month physical activity programme in lung cancer patients. <i>European Journal of Neurology</i> , 2021, 28, 1324-1333.	1.7	3
9	Late effects of cancer treatment: consequences for long-term brain cancer survivors. <i>Neuro-Oncology Practice</i> , 2021, 8, 18-30.	1.0	12
10	Duloxetine against symptomatic chemotherapy-induced peripheral neurotoxicity in cancer survivors: a real world, open-label experience. <i>Anti-Cancer Drugs</i> , 2021, 32, 88-94.	0.7	8
11	Precise enhancement quantification in post-operative MRI as an indicator of residual tumor impact is associated with survival in patients with glioblastoma. <i>Scientific Reports</i> , 2021, 11, 695.	1.6	21
12	Perilesional edema in brain metastases as predictive factor of response to systemic therapy in non-small cell lung cancer patients: a preliminary study. <i>Annals of Translational Medicine</i> , 2021, 9, 648-648.	0.7	2
13	Neuromuscular complications of cancer therapy. <i>Current Opinion in Neurology</i> , 2021, 34, 658-668.	1.8	4
14	Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity. <i>Neurology</i> , 2021, 97, e660-e672.	1.5	16
15	Senescence in neurons: an open issue. <i>Aging</i> , 2021, 13, 16902-16903.	1.4	0
16	Encephalitis Induced by Immune Checkpoint Inhibitors. <i>JAMA Neurology</i> , 2021, 78, 864.	4.5	61
17	Thymoma and Autoimmune Encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	28
18	Gossypol Treatment Restores Insufficient Apoptotic Function of DFF40/CAD in Human Glioblastoma Cells. <i>Cancers</i> , 2021, 13, 5579.	1.7	2

#	ARTICLE	IF	CITATIONS
19	Assessing risk factors of falls in cancer patients with chemotherapy-induced peripheral neurotoxicity. <i>Supportive Care in Cancer</i> , 2020, 28, 1991-1995.	1.0	17
20	Pathogenesis of platinum-induced peripheral neurotoxicity: Insights from preclinical studies. <i>Experimental Neurology</i> , 2020, 325, 113141.	2.0	49
21	Methods for in vivo studies in rodents of chemotherapy induced peripheral neuropathy. <i>Experimental Neurology</i> , 2020, 325, 113154.	2.0	39
22	RNU6-1 in circulating exosomes differentiates GBM from non-neoplastic brain lesions and PCNSL but not from brain metastases. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa010.	0.4	11
23	Emerging pharmacological strategies for the management of chemotherapy-induced peripheral neurotoxicity (CIPN), based on novel CIPN mechanisms. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 1005-1016.	1.4	16
24	Presurgical Identification of Primary Central Nervous System Lymphoma with Normalized Time-Intensity Curve: A Pilot Study of a New Method to Analyze DSC-PWI. <i>American Journal of Neuroradiology</i> , 2020, 41, 1816-1824.	1.2	16
25	Immune-Driven Pathogenesis of Neurotoxicity after Exposure of Cancer Patients to Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5774.	1.8	23
26	Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study. <i>Journal of Neuro-Oncology</i> , 2020, 148, 545-554.	1.4	25
27	Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: Experience beyond the clinical trials. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 171-177.	1.4	32
28	Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic. <i>Cancer Treatment Reviews</i> , 2020, 89, 102067.	3.4	48
29	Real world, open label experience with lacosamide against acute painful oxaliplatin-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 178-183.	1.4	8
30	Immune checkpoint inhibitors-induced neuromuscular toxicity: From pathogenesis to treatment. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, S74-S85.	1.4	42
31	Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, jnnp-2019-320969.	0.9	43
32	P10.04 Incidence and characteristics of neurological adverse events secondary to immunotherapy with checkpoint inhibitors. <i>Neuro-Oncology</i> , 2019, 21, iii41-iii41.	0.6	0
33	P14.93 The utility of the brain 18-FDG-PET and perfusion magnetic resonance imaging in the radionecrosis differential diagnosis. <i>Neuro-Oncology</i> , 2019, 21, iii89-iii90.	0.6	0
34	Voltage-gated sodium channel dysfunction and the search for other satellite channels in relation to acute oxaliplatin-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 360-361.	1.4	4
35	Liability of the voltage-gated potassium channel KCNN3 repeat polymorphism to acute oxaliplatin-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 298-303.	1.4	11
36	Bortezomib and other proteasome inhibitors-induced peripheral neurotoxicity: From pathogenesis to treatment. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, S52-S62.	1.4	30

#	ARTICLE	IF	CITATIONS
37	Cognitive and brain structural changes in long-term oligodendroglial tumor survivors. <i>Neuro-Oncology</i> , 2019, 21, 1470-1479.	0.6	22
38	GEINO 1402: A phase Ib dose-escalation study followed by an extension phase to evaluate safety and efficacy of crizotinib in combination with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed glioblastoma (GB). <i>Annals of Oncology</i> , 2019, 30, v147.	0.6	1
39	Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 111-119.	1.4	20
40	Contrast-enhancement in supratentorial low-grade gliomas: a classic prognostic factor in the molecular age. <i>Journal of Neuro-Oncology</i> , 2019, 143, 515-523.	1.4	11
41	Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 190-206.	2.0	8
42	MA13.03 Retrospective Study of Intrathecal Therapy for Non-Small Cell Lung Cancer (NSCLC) Patients with Leptomeningeal Carcinomatosis. <i>Journal of Thoracic Oncology</i> , 2019, 14, S300-S301.	0.5	1
43	P1.01-111 ATEZO-BRAIN, A Single-Arm Phase II Study of Atezolizumab Combined with Chemotherapy in Stage IV NSCLC Patients with Untreated Brain Metastases. <i>Journal of Thoracic Oncology</i> , 2019, 14, S405.	0.5	0
44	Radiological Characteristics and Natural History of Adult IDH-Wildtype Astrocytomas with TERT Promoter Mutations. <i>Neurosurgery</i> , 2019, 85, E448-E456.	0.6	20
45	Syndrome and outcome of antibody-negative limbic encephalitis. <i>European Journal of Neurology</i> , 2018, 25, 1011-1016.	1.7	103
46	Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve. <i>Supportive Care in Cancer</i> , 2018, 26, 3143-3151.	1.0	23
47	Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma. <i>JAMA Oncology</i> , 2018, 4, 495.	3.4	135
48	Performance monitoring in lung cancer patients pre- and post-chemotherapy using fine-grained electrophysiological measures. <i>NeuroImage: Clinical</i> , 2018, 18, 86-96.	1.4	13
49	Autonomic nervous system and cancer. <i>Clinical Autonomic Research</i> , 2018, 28, 301-314.	1.4	18
50	Brain functional connectivity in lung cancer population: an exploratory study. <i>Brain Imaging and Behavior</i> , 2018, 12, 369-382.	1.1	26
51	Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial. <i>Neurotherapeutics</i> , 2018, 15, 178-189.	2.1	92
52	Seizure-susceptible brain regions in glioblastoma: identification of patients at risk. <i>European Journal of Neurology</i> , 2018, 25, 387-394.	1.7	11
53	Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics. <i>Journal of Neuro-Oncology</i> , 2018, 136, 533-539.	1.4	16
54	OS1.1 Role of RNU6-1 isolated from circulating exosomes as a differential biomarker for GBM versus non-neoplastic brain lesions and PCNSL. <i>Neuro-Oncology</i> , 2018, 20, iii216-iii217.	0.6	0

#	ARTICLE	IF	CITATIONS
55	P05.21 T1-flair to T1-gadolinium MRI ratio as a predictive value of treatment response in non-small-cell lung cancer (NSCLC) patients affected by multiple brain metastases. <i>Neuro-Oncology</i> , 2018, 20, iii307-iii307.	0.6	0
56	Contrast enhancement in low grade gliomas: A classic prognostic factor in the molecular age. <i>Annals of Oncology</i> , 2018, 29, viii129.	0.6	0
57	Corrigendum. <i>Neuro-Oncology</i> , 2018, , .	0.6	0
58	OS3.3 Radiological characteristics and natural history of adult IDH wild type astrocytomas with TERT promoter mutations. <i>Neuro-Oncology</i> , 2018, 20, iii221-iii221.	0.6	0
59	Rechallenge with oxaliplatin and peripheral neuropathy in colorectal cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1793-1801.	1.2	20
60	Inconclusive evidence to support the use of minimally-invasive radiofrequency denervation against chronic low back pain. <i>Annals of Translational Medicine</i> , 2018, 6, 127-127.	0.7	3
61	Sphingolipid metabolism products: potential new players in the pathogenesis of bortezomib-induced neuropathic pain. <i>Annals of Translational Medicine</i> , 2018, 6, S78-S78.	0.7	1
62	Sigma-1 receptor: a new player in neuroprotection against chemotherapy-induced peripheral neuropathy. <i>Neural Regeneration Research</i> , 2018, 13, 775.	1.6	16
63	Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer. <i>Journal of Pain and Symptom Management</i> , 2017, 54, 701-706.e1.	0.6	39
64	Neuropathic Pain and Nerve Growth Factor in Chemotherapy-Induced Peripheral Neuropathy: Prospective Clinical-Pathological Study. <i>Journal of Pain and Symptom Management</i> , 2017, 54, 815-825.	0.6	36
65	Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics. <i>Nature Reviews Neurology</i> , 2017, 13, 492-504.	4.9	68
66	Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 2306.	3.8	1,619
67	P17.02â€€,Diagnostic delay and treatment options of Primary Central Nervous System Lymphoma in the last decade: preliminary results of first 50 patients from two Catalan institutions. <i>Neuro-Oncology</i> , 2016, 18, iv77-iv77.	0.6	0
68	P16.01â€€,Duloxetine in chemotherapy-induced peripheral neuropathy: experience beyond the clinical trial.. <i>Neuro-Oncology</i> , 2016, 18, iv76-iv76.	0.6	0
69	P11.07â€€,Atypical Meningioma: The impact of WHO 2007 criteria. <i>Neuro-Oncology</i> , 2016, 18, iv67-iv67.	0.6	0
70	P14.04â€€,Retreatment with oxaliplatin in CRC is safe in terms of neurotoxicity. <i>Neuro-Oncology</i> , 2016, 18, iv73-iv74.	0.6	0
71	Serum micronutrients and prealbumin during development and recovery of chemotherapyâ€€induced peripheral neuropathy. <i>Journal of the Peripheral Nervous System</i> , 2016, 21, 134-141.	1.4	10
72	Inhibition of the neuronal NFÎ²B pathway attenuates bortezomib-induced neuropathy in a mouse model. <i>NeuroToxicology</i> , 2016, 55, 58-64.	1.4	22

#	ARTICLE	IF	CITATIONS
73	Preradiotherapy MR Imaging: A Prospective Pilot Study of the Usefulness of Performing an MR Examination Shortly before Radiation Therapy in Patients with Glioblastoma. <i>American Journal of Neuroradiology</i> , 2016, 37, 2224-2230.	1.2	17
74	Brain damage following prophylactic cranial irradiation in lung cancer survivors. <i>Brain Imaging and Behavior</i> , 2016, 10, 283-295.	1.1	24
75	An intrinsic DFF40/CAD endonuclease deficiency impairs oligonucleosomal DNA hydrolysis during caspase-dependent cell death: a common trait in human glioblastoma cells. <i>Neuro-Oncology</i> , 2016, 18, 950-961.	0.6	17
76	Longitudinal Brain Changes Associated with Prophylactic Cranial Irradiation in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 475-486.	0.5	47
77	Early post-operative magnetic resonance imaging in glioblastoma: correlation among radiological findings and overall survival in 60 patients. <i>European Radiology</i> , 2016, 26, 1048-1055.	2.3	31
78	Lymphomatosis cerebri: a rare form of primary central nervous system lymphoma. Analysis of 7 cases and systematic review of the literature. <i>Neuro-Oncology</i> , 2016, 18, 707-715.	0.6	35
79	Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis. <i>Journal of the Peripheral Nervous System</i> , 2015, 20, 15-23.	1.4	34
80	Patient Management Problemâ€”Preferred Responses. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2015, 21, 541-556.	0.4	0
81	Patient Management Problem. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2015, 21, 535-540.	0.4	0
82	Taxane-Induced Peripheral Neurotoxicity. <i>Toxics</i> , 2015, 3, 152-169.	1.6	87
83	Studying Memory Encoding to Promote Reliable Engagement of the Medial Temporal Lobe at the Single-Subject Level. <i>PLoS ONE</i> , 2015, 10, e0119159.	1.1	7
84	Toxic Effects of Bortezomib on Primary Sensory Neurons and Schwann Cells of Adult Mice. <i>Neurotoxicity Research</i> , 2015, 27, 430-440.	1.3	31
85	Reliability and accuracy of quantitative sensory testing for oxaliplatin-induced neurotoxicity. <i>Acta Neurologica Scandinavica</i> , 2015, 131, 282-289.	1.0	16
86	Diagnostic and prognostic significance of flow cytometry immunophenotyping in patients with leptomeningeal carcinomatosis. <i>Clinical and Experimental Metastasis</i> , 2015, 32, 383-391.	1.7	49
87	Cognitive and Brain Structural Changes in a Lung Cancer Population. <i>Journal of Thoracic Oncology</i> , 2015, 10, 38-45.	0.5	79
88	Duloxetine in symptomatic chemotherapy-induced peripheral neuropathy: Single-center experience beyond the clinical trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20713-e20713.	0.8	0
89	O3.04 * COGNITIVE AND STRUCTURAL BRAIN CHANGES ASSOCIATED WITH PROPHYLACTIC CRANIAL IRRADIATION IN LONG TERM SMALL CELL LUNG CANCER SURVIVORS. <i>Neuro-Oncology</i> , 2014, 16, ii5-ii6.	0.6	0
90	Etiologic Spectrum and Prognosis of Longitudinally Extensive Transverse Myelopathies. <i>European Neurology</i> , 2014, 72, 86-94.	0.6	22

#	ARTICLE	IF	CITATIONS
91	Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. <i>Annals of Oncology</i> , 2014, 25, 257-264.	0.6	136
92	Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study. <i>Journal of the Peripheral Nervous System</i> , 2014, 19, 299-306.	1.4	67
93	Treatment with anti-TNF alpha protects against the neuropathy induced by the proteasome inhibitor bortezomib in a mouse model. <i>Experimental Neurology</i> , 2014, 253, 165-173.	2.0	39
94	Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 392-398.	0.9	116
95	Bortezomib-induced peripheral neurotoxicity: an update. <i>Archives of Toxicology</i> , 2014, 88, 1669-1679.	1.9	73
96	Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 919-923.	1.1	66
97	Oxaliplatin Neurotoxicity. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 303-312.	1.0	13
98	Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CIPN-R-ONS study. <i>Journal of the Peripheral Nervous System</i> , 2014, 19, 127-135.	1.4	36
99	Differences in cerebrospinal fluid inflammatory cell reaction of patients with leptomeningeal involvement by lymphoma and carcinoma. <i>Translational Research</i> , 2014, 164, 460-467.	2.2	7
100	Neurotoxicity induced by antineoplastic proteasome inhibitors. <i>NeuroToxicology</i> , 2014, 43, 28-35.	1.4	43
101	Clinical pattern and associations of oxaliplatin acute neurotoxicity. <i>Cancer</i> , 2013, 119, 438-444.	2.0	179
102	Impact of radiotherapy delay on survival in glioblastoma. <i>Clinical and Translational Oncology</i> , 2013, 15, 278-282.	1.2	50
103	Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS). <i>European Journal of Cancer</i> , 2013, 49, 2910-2918.	1.3	35
104	Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain. <i>Neuro-Oncology</i> , 2013, 15, 797-805.	0.6	77
105	Chemobrain: A systematic review of structural and functional neuroimaging studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 1311-1321.	2.9	152
106	Bevacizumab for the Treatment of Glioblastoma. <i>Clinical Medicine Insights: Oncology</i> , 2013, 7, CMO.S8503.	0.6	64
107	The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. <i>Annals of Oncology</i> , 2013, 24, 454-462.	0.6	232
108	Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study. <i>Cancer</i> , 2013, 119, 3570-3577.	2.0	86

#	ARTICLE	IF	CITATIONS
109	Advanced age and liability to oxaliplatin-induced peripheral neuropathy: a post hoc analysis of a prospective study. <i>European Journal of Neurology</i> , 2013, 20, 788-794.	1.7	30
110	Epilepsy in glioblastoma patients: basic mechanisms and current problems in treatment. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 333-344.	1.3	31
111	Role of flow cytometry immunophenotyping in the diagnosis of leptomeningeal carcinomatosis. <i>Neuro-Oncology</i> , 2012, 14, 43-52.	0.6	46
112	Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. <i>Annals of Oncology</i> , 2012, 23, 3116-3122.	0.6	69
113	Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 899-902.	1.1	37
114	Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients treated with standard chemoradiotherapy. <i>Journal of Neuro-Oncology</i> , 2012, 108, 451-458.	1.4	27
115	Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors. <i>Journal of Neuro-Oncology</i> , 2012, 109, 137-142.	1.4	38
116	Leptomeningeal Metastases. <i>Current Treatment Options in Neurology</i> , 2012, 14, 402-415.	0.7	22
117	Chemotherapy-induced peripheral neurotoxicity (CIPN): An update. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 82, 51-77.	2.0	441
118	Validation of the new graded prognostic assessment scale for brain metastases: a multicenter prospective study. <i>Radiation Oncology</i> , 2011, 6, 23.	1.2	51
119	Proton MR Spectroscopy Provides Relevant Prognostic Information in High-Grade Astrocytomas. <i>American Journal of Neuroradiology</i> , 2011, 32, 74-80.	1.2	33
120	Paraneoplastic Opsoclonus-Myoclonus Syndrome as a New and Single Manifestation of Relapsing Disease in a Patient with Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 968-969.	0.5	13
121	Evaluation of pre-existing neuropathy and bortezomib retreatment as risk factors to develop severe neuropathy in a mouse model. <i>Journal of the Peripheral Nervous System</i> , 2011, 16, 199-212.	1.4	21
122	Meningeal melanocytosis: a possibly useful treatment for a rare primary brain neoplasm. <i>Journal of Neurology</i> , 2011, 258, 1169-1171.	1.8	3
123	Stroke and carotid occlusion by giant non-hemorrhagic pituitary adenoma. <i>Acta Neurochirurgica</i> , 2011, 153, 2457-2459.	0.9	9
124	Refractory nonconvulsive status epilepticus in Creutzfeldt-Jakob disease. <i>Epileptic Disorders</i> , 2010, 12, 239-242.	0.7	17
125	Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients. <i>Journal of the Peripheral Nervous System</i> , 2010, 15, 17-25.	1.4	57
126	Chemotherapy-induced peripheral neuropathy: An unresolved issue. <i>Neurologia (English Edition)</i> , 2010, 25, 116-131.	0.2	25

#	ARTICLE	IF	CITATIONS
127	Can leptomeningeal myelomatosis be predicted in patients with IgD multiple myeloma?. Journal of Clinical Neuroscience, 2010, 17, 1071-1072.	0.8	9
128	Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice. Experimental Neurology, 2010, 223, 599-608.	2.0	85
129	Prospective validation of the new graded prognostic assessment scale for brain metastases: A multicenter study.. Journal of Clinical Oncology, 2010, 28, 2074-2074.	0.8	0
130	Leptomeningeal carcinomatosis. Cancer, 2009, 115, 381-389.	2.0	58
131	Sensory-motor polyradiculoneuropathy as the first manifestation of sternum bone plasmacytoma only revealed by bone scintigraphy. Neuromuscular Disorders, 2009, 19, 59-61.	0.3	1
132	Pelvic dyskinesia with an outstanding response to tetrabenazine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 847-848.	2.5	4
133	Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations. Cancer Management and Research, 2009, 1, 137.	0.9	7
134	Antibodies against disialosyl and terminal NeuNAc(1±2-3)Gal ganglioside epitopes in acute relapsing sensory ataxic neuropathy. Journal of Neurology, 2008, 255, 764-766.	1.8	13
135	Neuronal surface antigen antibodies in limbic encephalitis. Neurology, 2008, 71, 930-936.	1.5	189
136	Anti-Hu-associated brainstem encephalitis. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 80, 404-407.	0.9	95
137	Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma. Neuropathology, 2007, 27, 114-120.	0.7	148
138	Rapid eye movement sleep behavior disorder and potassium channel antibody-associated limbic encephalitis. Annals of Neurology, 2006, 59, 178-181.	2.8	213
139	Idiopathic acute transverse myelitis: a clinical study and prognostic markers in 45 cases. Multiple Sclerosis Journal, 2006, 12, 169-173.	1.4	43
140	Meningeal Lymphomatosis as the First Manifestation of Splenic Marginal Zone Lymphoma. International Journal of Hematology, 2005, 82, 63-65.	0.7	10
141	Meningeal carcinomatosis as the first manifestation of a transitional cell carcinoma of the bladder. Journal of Neuro-Oncology, 2003, 63, 63-67.	1.4	23